EMA, PIC/S to Revise Annex 1 Sterile Manufacturing Guidelines; PDA Offers Detailed Advice
This article was originally published in The Gold Sheet
Executive Summary
International authorities and global manufacturers are embracing the opportunity for a more scientific, risk-based approach to sterile manufacturing. The hard part will be agreeing on just what that is.
You may also be interested in...
Firms Look To Upgrade Aseptic Processing Lines As EU GMP Annex 1 Revision Takes Effect Globally
Sterile drug manufacturers get one year to comply with most revisions in updated EU, PIC/S and WHO GMP Annex 1 guideline. PDA survey hints at scale of challenge facing firms that still use traditional open filling lines, a practice expected to end under the Annex 1 revisions.
Sterile Drug GMPs: CCS Tool Could Help Bridge Compliance Gaps As Annex 1 Revisions Take Effect
Experts who led PDA’s interactions with EU, PIC/S and WHO authorities on first-ever comprehensive revision of sterile drug product manufacturing guidance recently shared insights on implementation priorities with the Pink Sheet.
EU Issues Plans For Significant Changes To Manufacturing Standards For Sterile Medicines
Long-awaited plans to change the EU guideline on manufacturing standards for sterile medicinal products are out for consultation. The proposals were drafted in cooperation with the World Health Organization and the international pharmaceutical inspectorate group, PIC/S, to ensure global alignment of standards.